Moreover, Exo-ITGB1 treatment inhibited pulmonary vascular remodeling, reduced inflammatory cytokine production, and slowed down PAH progression in a hypoxia-induced common PAH model [43]. The gene discussed is ITGB1; the disease is pulmonary arterial hypertension.